Q3 2026 Veru Inc Earnings Call Transcript
Key Points
- Veru Inc. (VERU) has fully enrolled its Phase IIb PLATEAU clinical trial with 239 patients, ahead of schedule, positioning the company for a key interim analysis in Q1 2027.
- The company received a notice of allowance from the USPTO for a key method-of-use patent covering enobosarm in combination with weight loss drugs, with claims extending to at least 2044, strengthening its intellectual property position.
- Veru Inc. (VERU) entered into a clinical supply agreement with Novo Nordisk, which will provide Wegovy at no charge for the PLATEAU trial, reducing development costs and establishing a strategic partnership.
- The company's cash position improved to $23.9 million as of June 30, 2026, up from $15.8 million, and is expected to fund operations beyond the interim analysis, providing financial stability.
- Veru Inc. (VERU) is targeting a large and growing market, with 41.5% of Medicare Part D enrollees (over 20 million patients) having obesity, and recent Medicare coverage for GLP-1 drugs starting July 2026 expands potential reimbursement.
- Veru Inc. (VERU) continues to report net losses, with a net loss of $7 million for the quarter and $15.1 million for the nine months ended June 30, 2026, indicating ongoing financial challenges.
- The company's cash runway is limited, with only $23.9 million in cash, and it may need to raise additional capital to fund the full development of enobosarm through Phase III trials.
- The Phase IIb PLATEAU trial is still in early stages, and the interim analysis results are not expected until Q1 2027, leaving significant clinical and regulatory uncertainty.
- Veru Inc. (VERU) faces intense competition in the obesity drug market, with major players like Eli Lilly and Novo Nordisk dominating, and the company's combination therapy approach may struggle to differentiate.
- The company's reliance on a single partner, Novo Nordisk, for the supply of semaglutide in its pivotal trial creates dependency risk, and the right of first negotiation granted to Novo Nordisk could limit future licensing opportunities.
Good morning, ladies and gentlemen, and welcome to Veru Inc.'s Investors conference call. (Operator Instructions) Please note that this event is being recorded.
I would now like to turn the conference call over to Mr. Sam Fisch, Veru Inc.'s Executive Director, Investor Relations and Corporate Communications. Please go ahead.
The statements made on this conference call may be forward-looking statements. Forward-looking statements may include, but are not necessarily limited to, statements of the company's plans, objectives, expectations or intentions regarding its business, operations, regulatory interactions, finances and development and product portfolio. Such forward-looking statements are subject to known and unknown risks and uncertainties and our actual results may differ significantly from those projected, suggested or included in any forward-looking statements. Risks that may cause actual results or developments to differ materially are contained in our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
